ArticleFrontiers in pediatrics2022
Severe pneumonia caused by human adenovirus type 55 in children.
Article in Frontiers in pediatrics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- A replication-incompetent adenovirus type 55 vaccine induces broad and durable protective immunity against pathogenic adenoviruses.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Establishment of a Cynomolgus Macaque Model for Human Adenovirus Type 55-Induced Respiratory Disease.The Journal of infectious diseases · 2026Article
- Adenovirus Types in US Children Hospitalized or Seen in the Emergency Department With Acute Respiratory Illness, 2016-2019.Open forum infectious diseases · 2025Article
- Clinical features of HAdV-55 in children with respiratory tract infections: a retrospective case series and literature review.BMC infectious diseases · 2025Review
- Isolation, genetic, and biological characterization of human adenovirus type 55 positive isolates from Wuhan, China.BMC infectious diseases · 2025Article
- Immunological pathogenesis and treatment progress of adenovirus pneumonia in children.Italian journal of pediatrics · 2025Review
- Phosphorylation Modifications and Their Role in Viral Pneumonia: Mechanisms and Therapeutic Implications.Infection and drug resistance · 2025Review
- Development and validation of a nomogram for predicting severe adenovirus pneumonia in children.Frontiers in pediatrics · 2025Article
- The value of combined examination of serum serum heparin binding protein, tumor necrosis factor alpha, interleukin-6, platelet count, and c-reactive protein in evaluating the condition and prognosis of children with adenovirus pneumonia.Frontiers in pediatrics · 2025Article
- Postinfectious Bronchiolitis Obliterans in Children.Canadian respiratory journal · 2025Review
- Neutralizing monoclonal antibodies protect against human adenovirus type 55 infection in transgenic mice and tree shrews.Emerging microbes & infections · 2024Article
- Prime-boost immunization with inactivated human adenovirus type 55 combined with an adjuvant enhances neutralizing antibody responses in mice.Virology journal · 2024Article
- Activation of the RIG-I/MAVS Signaling Pathway during Human Adenovirus Type 3 Infection Impairs the Pro-Inflammatory Response Induced by Secondary Infection withInternational journal of molecular sciences · 2024Article
- Combined intravenous ribavirin and recombinant human interferon α1b aerosol inhalation for adenovirus pneumonia with plastic bronchitis in children: a case report and review of literature.Frontiers in pediatrics · 2024Article
- Risk factors for pleural effusion in children with plastic bronchitis caused by pneumonia.Frontiers in pediatrics · 2024Article
- Abnormal liver function in children hospitalized with acute respiratory infection of adenoviruses: a retrospective study.Virologica Sinica · 2023Article
- Pediatric adenovirus pneumonia: clinical practice and current treatment.Frontiers in medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Emerging human adenovirus type 55 (HAdV-55) causes fatal pneumonia in adults. There is a lack of studies on severe pneumonia caused by HAdV-55 in children. Methods: We conducted a retrospective review of pediatric patients hospitalized at Guangzhou Women and Children's Medical Center with severe pneumonia from 2013 to 2020 who had human adenovirus (HAdV) detected in throat samples or bronchoalveolar lavage fluid using RT-PCR. The presence of HAdV-55 was determined by PCR amplification of the hypervariable regions of the hexon gene. Demographic, clinical, etiological, and outcome data were collected and analyzed. Results: Over the eight-year period, HAdV-55 was detected in three severe and six critical pediatric pneumonia patients. None of the patients had any underlying diseases, and had a median age of 18 months (range, 6-108 months). The male to female ratio was 2:1. All patients presented with fever and cough, and three patients presented with wheezing and diarrhea. Six patients had coinfections with other respiratory pathogens, such as bacteria, Mycoplasma pneumoniae and fungi. Three critical patients developed plastic bronchitis (PB). The median lengths of invasive mechanical ventilation and hospital stay of the critical patients were 10 (8, 28.75) days and 25 (13, 32.25) days, respectively. Three critical patients died, although two of them received extracorporeal membrane oxygenation (ECMO) and blood purification. Three surviving patients developed post-infectious bronchiolitis obliterans (PIBO) at the follow-up. Conclusions: HAdV-55 can cause fatal pneumonia in children, and shows a high rate of co-infection with other respiratory pathogens and a poorer prognosis combined with PB. Thus, HAdV-55 may be an important subtype in patients with HAdV-induced pneumonia who develop PIBO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.